focus -WSS

focus

author：entertainment 2025-10-01 11:45:32 - browse：9

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： FDA approves Sage Therapeutics’ rapid

focus

WSS

Blood tests recalled over risk of missed heart attack diagnosis

How I helped Pfizer think through the ethics of Viagra

FDA approves Sage Therapeutics’ rapid

Does aspartame cause cancer? What new WHO guidance says

Eli Lilly to acquire Versanis in heated race for weight loss drugs

How I helped Pfizer think through the ethics of Viagra

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Cancer drug shortages should be causing more outrage

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Hollywood unions extend contract negotiations for actors

How I helped Pfizer think through the ethics of Viagra

Alkermes shareholders re

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pharma showers House GOP doctor with campaign cash

Wikipedia

Why police arrested suspected Gilgo Beach killer away from his house

Study links childhood stress with decline in older age

Study links childhood stress with decline in older age

Mike Pence clashes with Tucker Carlson in Iowa

Georgia court denies Trump's request to quash DA's 2020 election probe

H.R. 3 is the wrong path to lower drug costs

focus

focus

leisure time

hotspot